Based on the February 5 denial by the Court of Appeals for the Federal Circuit of Indivior's appeals regarding the preliminary injunction against Dr. Reddy's Laboratories (RDY), the court should be issuing its mandate today, allowing Dr. Reddy's and Alvogen to come to market with their Suboxone generics, Lake Street analyst Thomas Flaten tells investors in a research note. The analyst values the Suboxone revenue stream at $2-$4 per Aquestive Therapeutics (AQST) share and believes any related downside is more than priced into the stock. As such, he reiterates a Buy rating on Aquestive with a $14 price target.